x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers

On a mission to disseminate information to the community and bridge the gap between academia and community oncology in this rapidly changing field of hematology & oncology. Drs. Rahul & Rohit Gosain interview world-renowned hematologists/oncologists to present the practice-changing data in a small bite-sized format where one could immediately apply that information in their daily practice to provide the best cancer care to their patients close to home. Privacy Policy:

health & fitness medicine

All Episodes

00:14:34

SABCS 2023 HER2+ Breast Cancer Highlights – APHINITY...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2024/01/11

In discussion with Dr. Daniel G. Stover, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 3 important practice informing studies in HER2+ disease with Dr. Stover: - APHINITY Sub-analysis: Benefit of Adj Pertuzumab and Trastuzumab According to ER and HER2 Expression - KATHERINE Update: Phase III Study of Adjuvant TDM-1 vs Trastuzumab for Residual Invasive HER2-positive Early Breast Cancer After Neoadj Chemo: Final IDFS and Updated OS

en

00:22:41

SABCS 2023 Breast Cancer Highlights – NATALEE,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2024/01/09

In discussion with Dr. Hope Rugo, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Rugo: - NATALEE Update – Ribociclib + Nonsteroidal AI as Adj Treatment in Patients with HR+/HER2− Early Breast Cancer: Final iDFS analysis - MONARCH 3 – Final OS Results of Abemaciclib Plus a Nonsteroidal AI as First-line Therapy for HR+, HER2– Advanced Breast Cancer - INAVO120 – Phase III Study of

en

00:21:04

ASH 2023 CLL/Lymphoma Highlights – ALPINE, SEQUOIA,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/12/21

In discussion with Dr. Mazyar Shadman from the Fred Hutch Cancer Center, covering the Chronic Lymphocytic Leukemia and Lymphoma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Shadman: - ALPINE: Ph 3, Extended Follow-up Confirms Sustained Superior PFS of Zanubrutinib vs Ibrutinib for Treatment of R/R Chronic Lymphocytic Leukemia and Small Lymphocytic

en

00:16:42

ASH 2023 Multiple Myeloma Highlights – PERSEUS,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/12/19

In discussion with Dr. Jens Hillengasss from Roswell Park Comprehensive Cancer Center, covering the Multiple Myeloma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Hillengass: - PERSEUS – Ph 3 Randomized Study of Dara + Bortezomib + Len + Dex (Dara-VRd) vs VRd Alone in Patients with NDMM Who Are Eligible for Autologous Stem Cell Transplantation (ASCT) -

en

00:17:13

SABCS 2023 Breast Cancer Highlights – NSABP B-51,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/12/15

In discussion with Dr. Eleonora Teplinsky, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Teplinsky: - NSABP B-51 – Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node Negative After Neoadjuvant Chemotherapy - IDEA Update – Five-year Outcomes of the IDEA trial of Endocrine Therapy Without Radiotherapy After

en

00:23:58

How to Treat Myelodysplastic Syndrome (MDS) with Dr....

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/11/24

In discussion with Dr. Amer Zeidan, covering how to treat myelodysplastic syndrome (MDS) in community settings. Dr. Zeidan is the director of early therapeutics research and associate professor of medicine at the Yale School of Medicine – Smilow Cancer Hospital. With Dr. Zeidan we covered MDS management in low-risk and high-risk patient population. #PrecisionMedicine #Hematology #Cancer #Malignancy #MDS #BloodCancer #oncology #oncbrothers

en

00:14:41

ESMO 2023 GI Cancer Highlights – Codebreak300,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/11/16

In discussion with Dr. Rachna Shroff, covering the ESMO 2023 GI Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Shroff: - Codebreak300 – Sotorasib plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer - CABINET – Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus - GASTFOX – Evaluate FOLFOX With or Without Docetaxel (TFOX) as First Line Chemotherapy for Locally

en

00:18:28

ESMO 2023 Lung Cancer - Chapter 2 Highlights –...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/11/13

In discussion with Dr. Alexander Spira, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Spira: - PAPILLON – Amivantamab Plus Chemo in Advanced NSCLC with EGFR Exon 20 Insertions - MARIPOSA – Amivantamab Plus Lazertinib Versus Osimertinib as First-line Treatment in EGFR-mutated Advanced NSCLC - MARIPOSA-2 – Amivantamab Plus Chemo (with or without Lazertinib) vs Chemo in EGFR-mutated Advanced NSCLC After

en

00:13:50

ESMO 2023 Breast Cancer Highlights – Keynote 756,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/11/09

In discussion with Dr. Erika Hamilton, covering the ESMO 2023 Breast Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Hamilton:- Keynote 756 – phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early stage, ER+/HER2- breast cancer, with better pCR seen in pembrolizumab arm- TROPION-Breast01 – Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in pre-treated inoperable

en

00:13:06

ESMO 2023 GU Cancer Highlights – SunRISE-1, EV-302,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/11/06

In discussion with Dr. Rana McKay, covering the ESMO 2023 GU Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. McKay: - SunRISE-1 – TAR-200 in Combination with Cetrelimab Versus TAR-200 Versus Cetrelimab in NMIBC unpresponsive to BCG - with TAR-200 mono therapy achieving 77% overall complete response rate - EV-302 – Enfortumab Vedotin and Pembrolizumab Versus Chemotherapy in Untreated Metastatic Urothelial Cancer, which showed

en

00:18:23

ESMO 2023 Lung Cancer Highlights – Keynote 671 |...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/11/02

In discussion with Dr. Joshua Reuss, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Reuss: - Keynote 671 – perioperative approach in non-small cell lung cancer with pembrolizumab and cisplatin based chemo combination, with positive OS data - ALINA – resectable non-small cell lung cancer pts with ALK positive disease, Alectinib will be the new standard of care given incredible DFS - TropionLung 01 –

en

00:24:05

How to Treat Cutaneous Melanoma - Deep Dive with Dr....

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/10/12

In discussion with Dr. Sapna Patel, Associate Professor, Director of the Uveal Melanoma, and Melanoma Fellowship Program Director at the MD Anderson Cancer Center we discuss how to treat Cutaneous Melanoma and important nuances from Community Oncology perspective. - Management of Stage 0/IA melanoma - where management is mainly surgery - Who is the most appropriate candidate for lymph node evaluation - Stage IIB and beyond, discussing choice of observation, radiation or immunotherapy especially

en

00:24:38

2023 World Conference on Lung Cancer Highlights | Dr....

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/09/21

In discussion with Dr. Stephen Liu, covering the World Conference on Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Liu: - FLAURA2 - studying the importance of Osimertinib + chemo vs. Osimertinib in EGFRm patients, PFS benefit in the combination arm, though pending OS and most benefit derived in patients with CNS mets - CHRYSALIS-2 - post progression on EGFR therapy, there is ORR benefit from adding Amivantamab in combination

en

00:23:14

How to Treat Chronic Lymphocytic Leukemia (CLL) with...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/09/14

In discussion with Dr. Jeff Sharman, about how to treat CLL. Chronic lymphocytic leukemia course has changed since we have started using BTK inhibitors. Dr. Sharman, director of hematology research at US Oncology Network and Director of Research at Willamette Valley Cancer Institute, was the first to ever give this medication here in the US. We discuss important nuances of CLL management with him, when to proceed with observation vs. treatment, when treating what BTKi to utilize, important side

en

00:21:25

Polatuzumab FDA Approval in DLBCL (POLARIX) & SWOG...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/08/31

Discussing two important lymphoma studies, POLARIX which led to the approval of Polatuzumab in DLBCL patients and SWOG S1826 comparing Nivolumab vs. BV with AVD in Hodgkin's Lymphoma patients with Dr. Jonathan Friedberg. In discussion with the lead author, Dr. Jonathan Friedberg - Director of Wilmot Cancer Institute, Professor of Medicine at University of Rochester Medical Center, and Editor-in-Chief at Journal of Clinical Oncology (JCO).

en

00:23:02

Story of Hope by a Determined Lung Cancer Survivor -...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/08/10

Discussing the story of hope and determination from the lung cancer survivor herself, Jill Feldman. Jill, talks about her lung cancer journey from limited stage to advanced stage with metastases, and how novel therapies have given her another chance of reliving her life, dreams and spending quality time with friends and family. Jill, has been an active patient advocate in the cancer space, and co-founder of the EGFR Positive Lung Cancer Resisters Advocacy Group.

en

00:15:52

EV-103 Study by Dr. Jonathan Rosenberg led to the FDA...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/07/31

Discussing the EV-103 Cohort K study, which resulted in the FDA approval of Enfortumab Vedotin + Pembrolizumab FDA Approval in the Cisplatin ineligible advanced urothelial carcinoma patients. In discussion with the lead author, Dr. Jonathan Rosenberg - Chief of Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center.

en

00:22:43

How to Treat MGUS and Smoldering Myeloma with Dr. S....

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/07/27

Discussing how to treat MGUS (Monoclonal gammopathy of undetermined significance) and Smoldering Myeloma using an algorithm with Dr. S. Vincent Rajkumar. We covered MGUS and smoldering myeloma in great detail, following with how these patients should be monitored and if any of these patients should be treated. Dr. S. Vincent Rajkumar is a world-renowned physician who specializes in plasma cell disorders - Professor of Medicine at the Mayo Clinic Comprehensive Cancer Center.

en

00:23:43

How to Treat Multiple Myeloma with Dr. Jens Hillengass

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/07/20

Discussing how to treat multiple myeloma using an algorithm with Dr. Jens Hillengass. We cover the first line, following that recurrence and refractory myeloma management in great detail. Dr. Jens Hillengass is the Chief of Myeloma, Professor of Oncology and Internal Medicine at the Roswell Park Comprehensive Cancer Center - University at Buffalo.

en

00:19:13

Critical Updates in Kidney, Prostate, and Bladder...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2023/07/06

Discussing GU (Genitourinary) Cancer ASCO 2023 Highlights, focusing on practice changing studies with Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology and Professor of Medicine at Harvard Medicine School - Dana-Farber Cancer Institute. Covering four important studies: - TALAPRO-2: Ph3 study of talazoparib + enzalutamide vs placebo + enzalutamide as first-line (1L) treatment for mCRPC with homologous recombination repair (HRR) gene alterations - CLEAR: 4-year follow-up of

en

197 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown